Social Behavior
BioNTech Chief Strategy Officer Departs Amid Oncology Pivot and Major Deals
BioNTech; chief strategy officer; Ryan Richardson; oncology pivot; CureVac acquisition; cancer pipeline; leadership transition
RFK Jr. Removes Top HHS Aides in Major Leadership Shakeup
RFK Jr.; Health and Human Services; leadership reshuffle; chief of staff; Matt Buckham; Heather Flick Melanson; Hannah Anderson; Trump loyalists; policy shakeup
RFK Jr. Fires Top HHS Leadership in Major Department Shakeup
RFK Jr.; HHS; leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; health policy; White House liaison
RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief
RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy
FDA Chief Calls for Lower User Fees as PDUFA VIII Negotiations Begin
FDA; user fees; PDUFA VIII; regulatory policy; drug approval; fee structure; negotiations
UnitedHealth Group Names Mike Cotton as New Medicaid CEO in Executive Reshuffle
UnitedHealth Group; CEO appointment; Medicaid; Mike Cotton; executive changes; government programs; Bobby Hunter; leadership transition
Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration
Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments
Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment
Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance
FDA Acting CDER Head Jacqueline Corrigan-Curay to Retire Amid Leadership Turnover
FDA; Jacqueline Corrigan-Curay; CDER; retirement; leadership turnover; drug regulation; agency departures
FDA’s Top Cell and Gene Therapy Leaders Exit Amid CBER Upheaval
FDA; cell therapy; gene therapy; CBER; Nicole Verdun; Rachael Anatol; Peter Marks; leadership changes; biopharma regulation